Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
BioCardia, Inc. is a clinical-stage biotechnology company developing autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases, including ischemic heart failure, chronic myocardial ischemia, and acute respiratory distress syndrome. Its core products include the CardiAMP autologous cell therapy system and CardiALLO allogeneic mesenchymal stem cell therapies, delivered via the proprietary Helix biotherapeutic delivery platform. BioCardia targets specialist cardiologists and medical centers, leveraging patented technologies and a direct sales model.
This description was generated via AI from an annual report. Updated about 1 year ago.